Evidence map›Paper›PMID 30232320›Full record

ArticleTranslational psychiatry2018

Urinary biomarker panel for diagnosing patients with depression and anxiety disorders.

Jian-Jun Chen, Shun-Jie Bai, Wen-Wen Li, Chan-Juan Zhou, Peng Zheng, Liang Fang, Hai-Yang Wang, Yi-Yun Liu, Peng Xie

Open access · goldAbstract read
In one paragraph

Article in Translational psychiatry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 3 pooled it
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 3 syntheses or guidelines pooled it, 109 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Peripheral S-(PGJBMC psychiatry · 2026
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Fast Label-Free Metabolic Profile Recognition Identifies Phenylketonuria and Subtypes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Jian-Jun ChenInstitute of Life Sciences, Chongqing Medical University, Chongqing, China.
Shun-Jie BaiDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Wen-Wen LiInstitute of Neuroscience, Chongqing Medical University, Chongqing, China.
Chan-Juan ZhouInstitute of Neuroscience, Chongqing Medical University, Chongqing, China.
Peng ZhengDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Liang FangInstitute of Neuroscience, Chongqing Medical University, Chongqing, China.
Hai-Yang WangDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Yi-Yun LiuDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Peng XieDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. xiepeng@cqmu.edu.cn.
Chongqing Medical University · CNFirst Affiliated Hospital of Chongqing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Available data indicate that patients with depression and anxiety disorders are likely to be at greater risk for suicide. Therefore, it is important to correctly diagnose patients with depression and anxiety disorders. However, there are still no empirical laboratory methods to objectively diagnose these patients. In this study, the multiple metabolomics platforms were used to profile the urine samples from 32 healthy controls and 32 patients with depression and anxiety disorders for identifying differential metabolites and potential biomarkers. Then, 16 healthy controls and 16 patients with depression and anxiety disorders were used to independently validate the diagnostic performance of the identified biomarkers. Finally, a panel consisting of four biomarkers-N-methylnicotinamide, aminomalonic acid, azelaic acid and hippuric acid-was identified. This panel was capable of distinguishing patients with depression and anxiety disorders from healthy controls with an area under the receiver operating characteristic curve of 0.977 in the training set and 0.934 in the testing set. Meanwhile, we found that these identified differential metabolites were mainly involved in three metabolic pathways and five molecular and cellular functions. Our results could lay the groundwork for future developing a urine-based diagnostic method for patients with depression and anxiety disorders.

Indexed as

AdultAnxiety DisordersBiomarkersCase-Control StudiesChinaDepressive DisorderDicarboxylic AcidsFemaleGas Chromatography-Mass SpectrometryHippuratesHumansLogistic ModelsMaleMalonatesMetabolomicsNiacinamideaminomalonic acidazelaic acidBiomarkersDicarboxylic AcidsHippurateshippuric acidMalonatesNiacinamideN-methylnicotinamide

Identifiers

PMID30232320
PMCPMC6145889
OpenAlexW2891961117

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.